The latest financial statement is for the quarter ending 2026-03-31.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Bad debt expense | - | - | 0 | 37 |
| Net income (loss), including portion attributable to noncontrolling interest | -3,405 | -4,142 | -7,244 | -3,803 |
| Credit loss expense | - | - | 3,849 | - |
| Stock option compensation expense | 699 | 1,014 | 844 | 1,107 |
| Common stock issued for services | 46 | 260 | 55 | 333 |
| Ppp forgiveness | - | 0 | 0 | 0 |
| Credit loss expense | 0 | 3,886 | - | - |
| Amortization of debt discount | 62 | 90 | 39 | 67 |
| Amortization of right-of-use operating lease assets | 49 | 42 | 51 | 55 |
| Finance lease right -of-use asset amortization | - | 113 | - | - |
| Amortization of right-of-use finance lease asset | -23 | - | 18 | 33 |
| Operating lease liabilities | -47 | -37 | -50 | -50 |
| Fair value of warrants issued for a fee and interest | - | 0 | - | - |
| Finance lease liability | 24 | 23 | 22 | 43 |
| Gain on investment in south korean joint venture | 0 | -23 | 0 | 9 |
| Depreciation expense | 34 | 33 | 34 | 78 |
| Accounts receivable | 115 | -144 | -410 | 2,368 |
| Inventories | -18 | -99 | -35 | 114 |
| Prepaid expenses and other assets | -3 | 237 | 22 | -33 |
| Accounts payable and accrued expenses-Entities Excluding Partially Owned Subsidiary | -135 | 321 | -539 | 484 |
| Deposits | -1 | 89 | 78 | -68 |
| Accounts payable and accrued expenses-Partially Owned Subsidiary | -168 | 372 | -139 | 144 |
| Contract liabilities | 39 | 280 | 0 | 0 |
| Net cash used in operating activities | -2,917 | -1,590 | -2,759 | -3,948 |
| Clyra medical note receivable | - | 0 | - | - |
| Repayment of note receivable | - | 0 | 289 | 192 |
| Equipment purchases | 32 | 13 | 33 | 0 |
| Net cash used in investing activities | -32 | -13 | 256 | 192 |
| Proceeds from sale of common stock, net of commissions | - | - | 749 | 793 |
| Proceeds from biolargo warrant exercise-Clyra Medical Technologies | - | 0 | 585 | 1,309 |
| Proceeds from debt obligation | - | - | 50 | - |
| Proceeds from warrant exercise | - | - | 0 | 0 |
| Proceeds from sale of common stock, net of offering costs | 256 | 2,027 | - | - |
| Proceeds from biolargo stock option exercise | - | 0 | 0 | 0 |
| Proceeds from clyra medical note payable-Partially Owned Subsidiary | - | 1,261 | - | - |
| Proceeds from sale of common stock, net of offering costs-Beti Common Stock | - | 425 | 0 | 0 |
| Common stock issued for financing fee | 85 | - | - | - |
| Repayment of debt obligations | -10 | - | 9 | 9 |
| Proceeds from biolargo warrant exercise-Biolargo Energy Technologies Inc BETI | - | 0 | - | - |
| Proceeds from beti unit offering-Biolargo Energy Technologies Inc BETI | 362 | - | 100 | - |
| Proceeds (repayments) from debt obligations, net | - | 24 | - | - |
| Proceeds from clyra medical preferred series b-Clyra Medical Preferred Stock Series B | - | - | 2,145 | - |
| Proceeds from note payable | - | - | - | 50 |
| Proceeds from sale of preferred stock in clyra medical-Partially Owned Subsidiary | - | 2,145 | - | - |
| Proceeds from clyra medical debt obligations | 1,134 | - | 0 | 1,261 |
| Proceeds from sale of common stock, net of offering costs-Clyra Medical Common Stock | 0 | 150 | 0 | 295 |
| Net cash provided by financing activities | 3,190 | 952 | 3,570 | 3,699 |
| Net effect of foreign currency translation | -2 | -12 | 8 | -20 |
| Net change in cash | 239 | -663 | 1,075 | -77 |
| Cash and cash equivalents at beginning of period | 3,883 | 4,546 | 3,548 | - |
| Cash and cash equivalents at end of period | 4,122 | 3,883 | 4,546 | - |
BIOLARGO, INC. (BLGO)
BIOLARGO, INC. (BLGO)